NIH-funded research R01 grant

Personalized prognosis and care for primary progressive aphasia

Official title: Toward Personalized Prognosis and Outcomes in Primary Progressive Aphasia

Funded at Massachusetts General Hospital · NIH-10973968 · Data updated 2026-11-12

This project will use brain scans and molecular imaging to help predict how language skills will change over time for people with primary progressive aphasia.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionMassachusetts General Hospital
NIH-funded
Lab location1 site (Boston, United States)
Project startApril 17, 2023
Project endMarch 31, 2028
Funding year2026
Award (this year)$823,683
NIH project number4R01NS131395-02
Project IDNIH-10973968 on NIH RePORTER

Who could benefit from this research

Could help

People with a diagnosis of primary progressive aphasia or suspected early PPA who can undergo MRI and PET scanning and attend follow-up visits would be the ideal candidates.

Less likely to help

Those without PPA, unable to undergo MRI/PET (for example because of incompatible implants or severe claustrophobia), or unable to travel to the study site may not be able to participate or benefit.

What this research studies

You would have PET scans that look for tau and amyloid proteins and several kinds of MRI (structural, diffusion, and functional) to map your language networks. The team will repeat imaging over time to see how your brain changes and which molecular pathology is driving your symptoms. That information will be used to give a more specific diagnosis and clearer predictions about language decline. The researchers aim to make these imaging methods into practical tools clinicians can use to guide care and future treatments.

Why it matters

Potential benefit: If successful, this work could give earlier and more specific diagnoses and clearer forecasts of decline to help patients plan care and match to targeted therapies.

How similar studies have gone: Prior smaller studies have shown promising results using tau and amyloid PET and advanced MRI in PPA, but combining these measures for routine clinical use is relatively new.

Where this research is happening

  • Massachusetts General Hospital
    Boston, United States
    Active

Researchers

  • Principal investigator: Dickerson, Bradford C — Massachusetts General Hospital
  • Study coordinator: Dickerson, Bradford C

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.